Peptides Targeting p53-MDM2: Reactivating p53 in Cancer

Anticancer Peptides

1,000x binding improvement

Stapled peptide ATSP-7041 achieved 1,000-fold greater binding affinity for MDM2 and MDMX compared to its linear parent sequence, restoring p53 activation in cancer cells.

Chang et al., PNAS, 2013

Chang et al., PNAS, 2013

View as image

The p53 protein is called the "guardian of the genome" because it triggers cell death or growth arrest when DNA damage is detected. In roughly half of all human cancers, p53 is mutated and non-functional. But in the other half, p53 is structurally intact yet silenced by its own negative regulators, MDM2 and MDMX. These two proteins bind p53's transactivation domain, block its transcriptional activity, and target it for proteasomal degradation. Peptide-based inhibitors of the p53-MDM2 interaction aim to release p53 from this suppression, reactivating the cell's own tumor-killing machinery. For the broader landscape of how peptides kill cancer cells, see our pillar article on anticancer peptides.

The p53-MDM2 interaction: why it matters for cancer

Under normal conditions, p53 protein levels are kept low by a negative feedback loop. When p53 activates transcription, one of its target genes is MDM2 itself. MDM2 protein then binds the transactivation domain of p53, blocking its function and tagging it with ubiquitin for degradation by the proteasome. The half-life of p53 in unstressed cells is roughly 20 minutes.^[1]

When DNA damage occurs, kinases phosphorylate both p53 and MDM2, disrupting their interaction. Free p53 accumulates, activates genes that halt cell division or trigger apoptosis, and the damaged cell is eliminated. This system fails in cancer through two common mechanisms: direct mutation of p53 (making it unable to bind DNA or activate transcription), or amplification of MDM2 and/or MDMX (overwhelming the damage-sensing pathway with excess inhibitor protein).

The second mechanism is the target for peptide intervention. If a molecule can physically block the MDM2-p53 binding interface, functional p53 accumulates and resumes its tumor-suppressive role. Iyer et al. estimated in a 2016 review that approximately 50% of all human cancers retain wild-type p53, making the MDM2/MDMX interaction one of the most broadly applicable targets in oncology.^[1]

The structural basis: three amino acids that define the interaction

The p53-MDM2 binding interface has been characterized at atomic resolution. A short alpha-helical segment of p53's transactivation domain (residues 15-29) inserts into a hydrophobic cleft on the surface of MDM2. Three p53 residues drive the interaction: phenylalanine-19, tryptophan-23, and leucine-26. These three side chains project from the same face of the helix into three sub-pockets in the MDM2 cleft.^[2]

This structural arrangement explains why peptide-based inhibitors have advantages over small molecules for this target. The binding interface is large (approximately 700 square angstroms), shallow, and primarily hydrophobic. Small molecules struggle to achieve sufficient contact area across such a broad, flat surface. Peptides that mimic the p53 alpha helix naturally replicate the three-dimensional arrangement of Phe19, Trp23, and Leu26, providing complementary binding geometry that small molecules must approximate through complex synthetic scaffolds.^[3]

Why MDMX matters as much as MDM2

Early drug development focused exclusively on MDM2 inhibitors. Several small-molecule MDM2 inhibitors (nutlins, idasanutlin, navtemadlin) entered clinical trials but showed limited single-agent activity in many tumor types. One reason became clear: MDMX.

MDMX (also called MDM4) is structurally related to MDM2 and independently suppresses p53 transcriptional activity. Unlike MDM2, MDMX does not have ubiquitin ligase activity, so it does not promote p53 degradation. Instead, it directly binds and blocks p53's transactivation domain. In tumors that overexpress both MDM2 and MDMX, inhibiting MDM2 alone frees p53 from degradation but leaves it transcriptionally blocked by MDMX.^[2]

This dual-suppression mechanism is where peptide inhibitors have a structural advantage. The p53 helix that binds MDM2 also binds MDMX through the same three key residues. A peptide that faithfully mimics this helix can disrupt both interactions simultaneously. Most small-molecule MDM2 inhibitors have poor affinity for MDMX because the MDMX binding cleft differs subtly in shape and electrostatics from MDM2's, and small molecules lack the conformational flexibility to accommodate both.

ATSP-7041 and ALRN-6924: the peptide MDM2/MDMX inhibitors

Chang et al. published the landmark 2013 PNAS study describing ATSP-7041, a stapled alpha-helical peptide that achieved dual nanomolar-affinity binding to both MDM2 (Kd = 0.9 nM) and MDMX (Kd = 6.8 nM). The 1,000-fold improvement in binding over the linear parent peptide came from hydrocarbon stapling, which locked the helical conformation and preorganized the Phe19-Trp23-Leu26 triad for optimal MDM2 engagement.^[2]

In cell-based assays, ATSP-7041 activated p53 signaling at submicromolar concentrations in cancer cell lines bearing wild-type p53, while having no effect on p53-null or p53-mutant cell lines, confirming on-target activity. In xenograft models, ATSP-7041 achieved dose-dependent tumor growth inhibition with complete tumor regression at the highest dose levels tested.

Guerlavais et al. published the full medicinal chemistry optimization in 2023, detailing how ATSP-7041 was refined into sulanemadlin (ALRN-6924), the clinical candidate. Key modifications included optimization of non-binding-face residues for cell permeability, adjustment of overall charge and amphipathicity for pharmacokinetic properties, and selection of a staple position that maximized serum stability without compromising binding.^[4]

Phase 1 clinical data showed dose-dependent pharmacokinetics, measurable p53 activation (confirmed by serum MIC-1 biomarker elevation), and evidence of antitumor activity in patients with TP53 wild-type solid tumors and lymphomas. The most common adverse events were gastrointestinal toxicity, fatigue, and reversible hematologic effects. A Phase 2a trial tested ALRN-6924 in combination with palbociclib (a CDK4/6 inhibitor) for MDM2-amplified tumors.^[4]

For more detail on the stapled peptide technology underlying ALRN-6924, see our article on peptide stapling.

The chemoprotection pivot: a second application

Beyond direct antitumor activity, ALRN-6924 was also explored as a chemoprotective agent. The concept: in patients whose tumors carry p53 mutations (making them insensitive to p53 activation), brief treatment with ALRN-6924 before chemotherapy could activate p53 in normal cells, transiently arresting their cell cycle and protecting them from chemotherapy-induced damage. The p53-mutant tumor cells would be unaffected by ALRN-6924 and remain vulnerable to the chemotherapy.^[4]

This application inverted the traditional paradigm: instead of using p53 activation to kill cancer cells, it used p53 activation to protect healthy cells. Clinical testing explored this approach for myelopreservation during chemotherapy. The clinical program has had limited advancement since early results, partly reflecting the challenges of demonstrating chemoprotection in controlled trials and partly reflecting the broader difficulties facing the stapled peptide drug class.

Computational design rules for p53 peptide inhibitors

Chandramohan et al. published design rules in Nature Communications (2024) that advance the field from empirical optimization toward rational design. Using molecular dynamics simulations across 82 stapled peptide variants targeting Mdm2/X, they identified three predictive factors: solvent-exposed staple placement, alpha-helical content above 60%, and calculated cell permeability scores.^[5]

The most striking finding was predictive accuracy. The design rules correctly identified which of 20 novel peptide designs would achieve in vivo tumor regression, before the compounds were synthesized or tested. This represents a shift from the traditional make-and-test cycle toward computationally guided design that could accelerate peptide drug development for p53-MDM2 and other protein-protein interaction targets.^[5]

Peptide approaches beyond the MDM2 cleft

FOXO4-p53 peptide inhibitors for senescent cells

In a different application of p53 biology, Kang et al. reported in 2025 on peptide inhibitors targeting the FOXO4-p53 interaction. In senescent cells, the FOXO4 transcription factor binds and sequesters p53, preventing it from triggering apoptosis. This allows senescent cells to persist and secrete inflammatory factors that promote cancer progression and tissue dysfunction.^[6]

The FOXO4-p53 disrupting peptides selectively killed senescent cancer cells while sparing non-senescent cells. This senolytic approach differs from direct MDM2 inhibition: instead of reactivating p53 in all wild-type cells, it specifically releases p53 in senescent cells where FOXO4-mediated sequestration keeps them alive. The therapeutic implication is a targeted senolytic peptide that could be used to clear senescent cells in the tumor microenvironment.

Restoring p53 helix conformation

Liu et al. demonstrated in 2022 that a peptide designed to restore the native alpha-helical conformation of the p53 binding domain could inhibit MDM2 without traditional hydrocarbon stapling. The approach used side-chain-to-side-chain hydrogen bonding to stabilize the helix, achieving MDM2 inhibition with improved cell permeability compared to unmodified p53 peptides.^[3]

p53 peptide membrane permeation

Li et al. published 2024 data in JACS using solid-state NMR to determine how p53 peptides cross cell membranes. The study revealed that membrane permeation involves partial unfolding of the peptide at the membrane surface, followed by insertion in a tilted orientation relative to the lipid bilayer. This mechanistic understanding could guide the design of next-generation p53 peptide inhibitors with improved intracellular delivery.^[7]

Peptides vs. small molecules: where peptides have the edge

The p53-MDM2 interaction has been targeted by both small molecules and peptides, providing a direct comparison of the two drug modalities for the same target.

Small molecules (nutlins, idasanutlin, navtemadlin, milademetan) bind the MDM2 cleft effectively but generally lack affinity for MDMX. They achieve oral bioavailability but frequently cause dose-limiting hematologic toxicity from excessive p53 activation in bone marrow progenitor cells. Several small-molecule MDM2 inhibitors have advanced to Phase 2 and 3 trials, with milademetan receiving approval in Japan for liposarcoma in 2023.

Stapled peptides achieve dual MDM2/MDMX inhibition but require injection. They can be designed with tunable pharmacokinetics and potentially a wider therapeutic window because their binding kinetics differ from small molecules. The clinical track record is thinner, with only ALRN-6924 having reached advanced trials.^[8]

The fundamental trade-off is oral convenience versus biological fidelity. Small molecules sacrifice some binding specificity for oral dosing. Peptides achieve superior target engagement by mimicking the natural p53 helix but face delivery challenges. Both classes face the same biological problem: p53 activation is powerful but can damage normal tissues, particularly bone marrow and the gastrointestinal epithelium. This relates to the broader challenge of how amphipathic peptides target specific cells.

What limits the clinical progress

Narrow patient selection. Only tumors with wild-type p53 AND MDM2/MDMX overexpression are expected to respond. This requires biomarker testing that is not yet standardized in clinical practice. Patients with p53 mutations (the other 50% of cancers) would not benefit.

On-target toxicity. Activating p53 everywhere in the body causes apoptosis in rapidly dividing normal cells, particularly in bone marrow. The therapeutic window between tumor cell killing and normal tissue damage remains narrow for all p53 reactivation approaches, whether peptide or small molecule.

Competition from small molecules. Milademetan's 2023 approval in Japan validated the p53-MDM2 mechanism clinically. Oral small molecules with established manufacturing and regulatory pathways may limit the commercial opportunity for injectable peptide alternatives unless peptides demonstrate clearly superior efficacy from dual MDM2/MDMX inhibition.

No approved peptide inhibitor. ALRN-6924 demonstrated proof-of-concept but has not achieved registration. The technology remains validated in principle but unproven as a marketed drug for this target.

The Bottom Line

Peptide inhibitors of the p53-MDM2 interaction exploit a natural structural advantage: the p53 transactivation domain binds MDM2 through an alpha-helical interface that peptides can mimic with high fidelity. Stapled peptides like ALRN-6924 achieved dual MDM2/MDMX inhibition in clinical trials, computational design rules now predict in vivo activity before synthesis, and new directions like FOXO4-p53 senolytic peptides expand the application space. The field is constrained by narrow patient selection (wild-type p53 only), on-target normal tissue toxicity, and competition from oral small molecules that target MDM2 alone.

Frequently Asked Questions

What is the p53-MDM2 interaction in cancer?

MDM2 is a protein that binds the tumor suppressor p53, blocking its ability to activate genes that stop cancer cell growth and trigger cell death. In approximately 50% of human cancers, p53 is structurally normal but held inactive by MDM2 and the related protein MDMX. Drugs that disrupt this interaction release functional p53, allowing it to resume its role as the "guardian of the genome" and suppress tumor growth.

How do peptide MDM2 inhibitors work?

Peptide MDM2 inhibitors mimic the alpha-helical portion of p53 that naturally binds to MDM2. Three p53 residues (phenylalanine-19, tryptophan-23, leucine-26) are critical for this interaction. Stapled peptide inhibitors lock this helical structure with a hydrocarbon bridge, achieving binding affinities up to 1,000 times stronger than the unmodified p53 peptide. By occupying the p53 binding site on MDM2, the peptide prevents MDM2 from suppressing endogenous p53.

What is ALRN-6924 sulanemadlin?

ALRN-6924 (sulanemadlin) is a stapled peptide developed by Aileron Therapeutics that inhibits both MDM2 and MDMX, the two primary suppressors of p53. It was the first cell-permeating stabilized alpha-helical peptide to enter human clinical trials. Phase 1 data showed dose-dependent p53 activation and evidence of antitumor activity. It has been tested both as a direct antitumor agent and as a chemoprotective agent to shield healthy cells during chemotherapy.

Are p53 MDM2 inhibitors FDA approved?

No p53-MDM2 peptide inhibitor is FDA approved as of early 2026. The small-molecule MDM2 inhibitor milademetan received approval in Japan for liposarcoma in 2023 but has not been approved in the US or EU. ALRN-6924, the most advanced peptide inhibitor, completed Phase 1 and Phase 2a clinical trials but has not achieved regulatory approval. Several other small-molecule and peptide MDM2 inhibitors remain in clinical development.

Why are peptides better than small molecules for MDM2?

Peptide inhibitors of MDM2 have one key structural advantage: they can simultaneously inhibit both MDM2 and MDMX by mimicking the natural p53 alpha helix that binds both proteins. Most small-molecule MDM2 inhibitors have poor affinity for MDMX because its binding cleft differs subtly in shape. However, small molecules have the advantage of oral bioavailability, while peptide inhibitors require injection. The clinical question is whether dual MDM2/MDMX inhibition provides sufficient efficacy improvement to justify injectable delivery.

What cancers can p53 reactivation peptides treat?

P53 reactivation peptides can potentially treat any cancer that retains wild-type (non-mutated) p53, which includes approximately 50% of all human cancers. The most promising applications are in tumors with MDM2 gene amplification, which include certain soft tissue sarcomas, breast cancers, and hematologic malignancies. Cancers with p53 mutations would not respond to this approach because the released p53 protein would still be non-functional.